Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-009 in FGF19-Positive Advanced Hepatocellular Carcinoma
NCT07547553Phase 2Recruiting
- Sponsor
- Huahui Health
- Start
- May 2026
- Primary completion
- Oct 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HH-009 in hepatocellular carcinoma (HCC), sponsored by Huahui Health. Started May 2026; status: recruiting.
02
Drugs
HH-009
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07547553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07547553.